22 min listen
A New Class of Cancer Therapies Targets Solid Tumors with a Dual Action
FromThe Bio Report
ratings:
Length:
22 minutes
Released:
Mar 10, 2022
Format:
Podcast episode
Description
Virus-like drug conjugates, or VDCs, are a new class of cancer therapies Aura Biosciences is developing to target a broad range of solid tumors. These therapies have a dual mechanism of action. They deliver a toxic payload to cancer cells, but also activate a secondary immune mediated response to kill cancer cells. We spoke to Elisabet de los Pinos, CEO of Aura Biosciences, about the company’s VDCs, how they work, and its pipeline in development.
Released:
Mar 10, 2022
Format:
Podcast episode
Titles in the series (100)
The Year in Biotech So Far and What’s Ahead: The biotech sector surged in the first half of the year despite volatile markets. M&A and financing continued to be robust as EvaluatePharma weighed in with its Pharma & Biotech Half-Year Report. We spoke to Jonathan Gardner, deputy news editor of EP... by The Bio Report